![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2149Y GW Pharmaceuticals PLC 10 February 2006 Embargoed until 0700 10 February 2006 GW Pharmaceuticals plc ("GW" or "the Company") Changes to Non-Executive Directors GW Pharmaceuticals today announces the appointment of Mr David Morrison as a non-executive director with immediate effect. Mr Morrison replaces Mr Peter Mountford, who today resigns as a non-executive director. David Morrison is Chief Executive of Prospect Investment Management, an investment advisory firm. Clients of Prospect are shareholders in GW. David began his career with 3i Group, followed by 13 years with Abingworth Management Limited. David is also a non-executive director of a large number of public and private companies, including Paypoint plc, Venture Production plc, BlueHeath Holdings plc, MessageLabs Group Ltd, MGT plc, Standard Life Equity Investment Trust plc and UK Specialist Hospitals Ltd. Dr Geoffrey Guy, Executive Chairman of GW, said: "We are delighted to welcome David to the Board of GW. David is a valued advisor to, and investor in, a range of public and private companies and his expertise is ideally suited to GW as it embarks on the next phase of its growth." Commenting on the resignation of Peter Mountford, Dr Guy, said, "Peter has been a non-executive director of GW for five years. Peter's extensive experience as an investor in and advisor to emerging companies was instrumental in helping us to successfully float on the AIM market in June 2001 and he has continued to be a valuable member of the Board since that time. Everyone at GW joins me in thanking Peter and wishing him all the best and continued success in his other business ventures." Peter Mountford owns warrants to subscribe for up to 51,765 ordinary shares in the capital of the Company which originally expired on 14 January 2006. The Board has agreed to extend the exercise period such that the warrants may be exercised at any time on or before 14 January 2008. - Ends - Enquiries: GW Pharmaceuticals plc + 44 (0)1980 557000 Dr Geoffrey Guy, Executive Chairman Justin Gover, Managing Director Weber Shandwick Square Mile + 44 (0)20 7067 0700 Kevin Smith Appendix DAVID MORRISON - LIST OF CURRENT AND FORMER DIRECTORSHIPS Current directorships: UK Specialist Hospitals Limited Shepton Mallet Treatment Centre Limited Blueheath Holdings plc Standard Life Equity Investment Trust plc R.H.S. Enterprises Limited Vibration Technology Limited Luckington Properties Limited MGt plc MGt Trustee Limited MessageLabs Group Limited Venture Production plc PayPoint plc PayPoint Collections Limited PayPoint Retails Solutions Limited PayPoint Network Limited The Houghton Club Limited Prospect Investment Management Limited Former directorships held since 8 February 2001: Blue Heath Direct Limited Arundel House Enterprises Limited There are no further disclosures to be made in respect of David Morrison pursuant to paragraph (f) of Schedule 2 of the AiM Rules for companies. This information is provided by RNS The company news service from the London Stock Exchange END BOABRGDDRXGGGLC
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions